Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility
Legacy of Health Information and Safety Evaluation
The legacy of general health and science information has long served as a foundation for public understanding of disease prevention and treatment. Within this framework, discussions of therapeutic interventions have traditionally focused on benefits and broad safety profiles, often emphasizing the balance between clinical efficacy and patient well-being. This heritage provides a structured approach to evaluating medical products, from initial development through post-market surveillance. As we pivot from this general health context to a specific occupational exposure concern, it becomes necessary to apply the same rigorous analytical lens to the relationship between pharmaceutical agents and adverse outcomes. In the domain of mass production, where workers may encounter biological or chemical agents during manufacturing processes, the transition from therapeutic context to exposure risk requires careful consideration.
Bridge from General Health to Occupational Exposure
The case of avelumab, a monoclonal antibody used in oncology, illustrates this pivot: while its clinical application targets cancer cells, the potential for unintended consequences in occupational settings—such as the theoretical risk of carcinogenesis—demands scrutiny. This shift in perspective moves the discussion from patient-centered outcomes to worker safety, where the biological plausibility of exposure-related harm must be evaluated without invoking specific disease mechanisms. The bridge concept thus reframes the legacy of health information to address emerging questions in industrial hygiene and pharmacovigilance.
Avelumab: Mechanism and Clinical Use in Merkel Cell Carcinoma
Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication, and it is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Biological Plausibility of Avelumab Causing Merkel Cell Carcinoma
The biological plausibility of a causal relationship between avelumab and the development or progression of Merkel cell carcinoma must be examined carefully. MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors (ICIs), including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, the mechanism of action of avelumab—blocking PD-L1 to enhance T-cell activity against tumor cells—is intended to treat MCC, not cause it. In clinical practice, avelumab is used as a therapeutic agent for advanced MCC, and response rates to PD-1/PD-L1 inhibition in metastatic disease can reach up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these benefits, approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This progression is generally attributed to primary or acquired resistance to the drug, not to avelumab causing new MCC.
Evidence Against Causation and Risk Context
There is no evidence in the provided sources that avelumab directly causes Merkel cell carcinoma. Instead, the literature focuses on avelumab as a treatment for MCC and on management strategies for patients who become refractory to it. For example, in avelumab-refractory patients, combined ipilimumab plus nivolumab has been investigated as a subsequent therapy, with three out of five patients in one study responding to this combination according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Additionally, a retrospective study noted that ICIs offer durable responses and significant clinical benefit, with avelumab and pembrolizumab approved for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). In terms of safety communication, the known adverse effects of avelumab include immune-related adverse events such as hypercalcemia due to reactivation of sarcoidosis, as described in a case report of a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). That patient's hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while avelumab can trigger immune overactivation, it does not cause MCC; rather, it is used to treat the disease.
Clinical Interpretation and Conclusion
For affected patients, a causation-focused clinical interpretation must consider the timeline between exposure and health outcomes. In the context of MCC, patients are typically diagnosed with the disease before receiving avelumab. The drug is administered as a treatment for existing MCC, not as a causative agent. Therefore, any new or worsening MCC after avelumab exposure is more likely due to disease progression or resistance rather than drug-induced carcinogenesis. The provided evidence does not support a mechanism by which avelumab induces de novo MCC. Instead, the biological plausibility aligns with avelumab's role as an immune checkpoint inhibitor that can lead to tumor regression in some patients and immune-related adverse events in others. In summary, the evidence indicates that avelumab is an effective treatment for metastatic MCC and does not cause the disease. The risk narrative should emphasize that avelumab is approved for MCC therapy, and any adverse outcomes are related to immune activation or treatment resistance, not causation of MCC.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
Frequently Asked Questions
Can avelumab cause Merkel cell carcinoma?
No, there is no evidence that avelumab causes Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor used to treat metastatic MCC. The drug works by blocking PD-L1 to enhance T-cell activity against tumor cells. While it can cause immune-related adverse events, it does not induce de novo MCC. Disease progression after avelumab is typically due to resistance, not causation.
What is the biological plausibility of avelumab causing cancer?
The biological plausibility of avelumab causing MCC is not supported. MCC is associated with UV exposure and Merkel cell polyoma virus, not with avelumab. Avelumab's mechanism is to treat existing cancer by activating the immune system. Although immune overactivation can lead to side effects, it does not create new cancer cells. The literature consistently describes avelumab as a treatment, not a cause, of MCC.
Does submitting information create an medical context-client relationship?
No. Submission requests an initial records screening only and does not create an medical context-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.